March 27, 2019
DURHAM, N.C.–(BUSINESS WIRE)–Bioventus, a global leader in orthobiologic solutions, is launching OSTEOAMP SELECT Fibers, an innovative addition to its allograft line of OSTEOAMP bone graft substitutes for spine, foot & ankle, orthopaedic, and trauma surgeons. OSTEOAMP SELECT Fibers are uniquely processed to retain essential growth factors supporting bone formation1* and the nanotextured fibers provide a conduit for cell migration.
OSTEOAMP SELECT Fibers also advance the handling properties of allograft bone graft substitutes by providing versatile handling for users. The interlocking fibers have high fluid retention and the ability to expand, while maintaining integrity and position.2 These handling properties allow it to be easily molded and packed into place to conform to irregular bone voids.
“OSTEOAMP SELECT Fibers have already been successfully utilized in multiple procedure types in both spine and foot and ankle specialties. Its absorption profile and ability to expand provide surgeons with clinical flexibility as the interlocking fibers can be easily molded and packed to conform to any bone void,” said Tony Bihl, CEO, Bioventus. “This new allograft solution joins our original OSTEOAMP offerings in putty, sponge and granule formats, giving surgeons more options for bone healing and remodeling while delivering positive patient outcomes.”
OSTEOAMP SELECT Fibers comes in five sizes from 1 to 15 cc and is available now from distributors nationwide. To learn more, visit https://www.BioventusSurgical.com/OSTEOAMPSELECT
About Bioventus
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal.
Bioventus, the Bioventus logo and OSTEOAMP are registered trademarks of Bioventus LLC.
References:
1. Tidwell JL., Seaman SA, Vanderploeg EJ, Tom S. In vitro and in vivo characterization of OSTEOAMP allogenic morphogentic proteins. Data on file. Bioventus white paper, 2017.
2. Data on file RPT-000858. OSTEOAMP Absorption Data.
*In vitro performance may not be predictive of performance in humans.
Summary of Indications for Use
OSTEOAMP may be used in situations where an autograft is appropriate. It should be restricted to homologous use for the repair, replacement, or reconstruction of musculoskeletal defects. Please see instructions for use for a complete list of indications, contraindications, warnings, and precautions on the product label, atwww.bioventussurgical.com or by calling 1-800-637-4391.
Contacts
Thomas Hill
919-474-6715
thomas.hill@bioventusglobal.com
